Professor Isla Mackenzie

Isla Mackenzie is Professor of Cardiovascular Medicine and Honorary Consultant Physician at the University of Dundee and Ninewells Hospital, Dundee.  She is the Associate Dean for Research for the School of Medicine and the Director of MEMO Research and the Hypertension Research Centre (HRC), University of Dundee.  Professor Mackenzie completed Clinical Pharmacology and Therapeutics and General Internal Medicine specialist training in Cambridge.  She leads clinical research studies in cardiovascular disease and drug safety and has an interest in decentralised clinical trials.  Clinical interests include hypertension and cardiovascular risk reduction. Professor Mackenzie sits on several national committees relating to clinical pharmacology and cardiovascular medicine including the British Heart Foundation Clinical Studies Committee and the British and Irish Hypertension Society Collaborative Research Standing Committee.

A few of Professor Isla Mackenzie’s Publications:

1. Mackenzie IS, Hawkey CJ, Ford I, Greenlaw N, Pigazzani F, Rogers A, Struthers AD, Begg A, Wei L, Avery A, Taggar J, Walker A, Duce SL, Barr RJ, Dumbleton J, Rooke ED, Townend JN, Ritchie LD, MacDonald TM on behalf of the ALL-HEART study group. Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: a multicentre, prospective, randomised, open-label, blinded endpoint clinical trial. The ALL-HEART study. Lancet 2022;400:1195-205.
2. Mackenzie IS, Rogers A, Poulter NR, Williams B, Brown MJ, Webb DJ, Ford I, Rorie D, Guthrie G, Grieve JWK, Pigazzani F, Rothwell PM, Young R, McConnachie A, Struthers AD, Lang CC, MacDonald TM on behalf of the TIME study group. Cardiovascular outcomes in adults with hypertension allocated to evening or morning dosing of usual antihypertensives: a prospective, randomised, open-label, blinded-endpoint clinical trial. The TIME study. Lancet 2022; 400:1417-25.
3. Chen A, Ju C, Mackenzie IS, MacDonald TM, Struthers AD, Wei L, Man KKC. Impact of beta-blockers on mortality and cardiovascular disease outcomes in patients with obstructive sleep apnoea: a population-based cohort study in target trial emulation framework. Lancet Regional Health – Europe 2023; 33:100715. https://doi.org/10.1016/j.lanepe.2023.100715
4. Mackenzie IS, Hawkey CJ, Ford I, Greenlaw N, Pigazzani F, Rogers A, Struthers AD, Begg AG, Wei L, Avery AJ, Taggar JS, Walker A, Duce SL, Barr RJ, Dumbleton JS, Rooke ED, Townend JN, Ritchie LD, MacDonald TM, on behalf of the ALL-HEART Study Group. Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluation. Health Technology Assessment 2024; 28(18). https://doi.org/10.3310/ATTM4092.
5. Pigazzani F, Dyar KA, Morant SV, Vetter C, Rogers A, Flynn RWV, Rorie DA, Mackenzie IS, Cappuccio DP, Manfredini R, MacDonald TM. Effect of timed dosing of usual antihypertensives according to patient chronotype on cardiovascular outcomes: the Chronotype sub-study cohort of the Treatment in the Morning versus Evening (TIME) study. eClinicalMedicine 2024;72. https://doi.org/10.1016/j.eclinm.2024.102633